JP2014517025A5 - - Google Patents

Download PDF

Info

Publication number
JP2014517025A5
JP2014517025A5 JP2014515214A JP2014515214A JP2014517025A5 JP 2014517025 A5 JP2014517025 A5 JP 2014517025A5 JP 2014515214 A JP2014515214 A JP 2014515214A JP 2014515214 A JP2014515214 A JP 2014515214A JP 2014517025 A5 JP2014517025 A5 JP 2014517025A5
Authority
JP
Japan
Prior art keywords
glioblastoma
compound
modified
hydrogen
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014515214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014517025A (ja
JP6228113B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/061485 external-priority patent/WO2012172069A1/en
Publication of JP2014517025A publication Critical patent/JP2014517025A/ja
Publication of JP2014517025A5 publication Critical patent/JP2014517025A5/ja
Application granted granted Critical
Publication of JP6228113B2 publication Critical patent/JP6228113B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014515214A 2011-06-15 2012-06-15 グリア芽腫阻害化合物およびその使用 Expired - Fee Related JP6228113B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161497215P 2011-06-15 2011-06-15
US61/497,215 2011-06-15
PCT/EP2012/061485 WO2012172069A1 (en) 2011-06-15 2012-06-15 Glioblastoma inhibiting compounds and their use

Publications (3)

Publication Number Publication Date
JP2014517025A JP2014517025A (ja) 2014-07-17
JP2014517025A5 true JP2014517025A5 (https=) 2016-03-31
JP6228113B2 JP6228113B2 (ja) 2017-11-08

Family

ID=46319762

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014515214A Expired - Fee Related JP6228113B2 (ja) 2011-06-15 2012-06-15 グリア芽腫阻害化合物およびその使用

Country Status (14)

Country Link
US (1) US9573960B2 (https=)
EP (1) EP2721035B1 (https=)
JP (1) JP6228113B2 (https=)
CN (1) CN103764659A (https=)
AU (1) AU2012268984B2 (https=)
BR (1) BR112013032360A2 (https=)
CA (1) CA2838945A1 (https=)
CL (1) CL2013003563A1 (https=)
IL (1) IL229767A0 (https=)
MX (1) MX340816B (https=)
PH (1) PH12013502530A1 (https=)
RU (1) RU2014101070A (https=)
WO (1) WO2012172069A1 (https=)
ZA (1) ZA201309365B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014023329A1 (en) 2012-08-06 2014-02-13 Life And Brain Gmbh Niclosamide and its derivatives for use in the treatment of solid tumors
US10905665B2 (en) 2015-06-24 2021-02-02 Duke University Chemical modulators of signaling pathways and therapeutic use
CA2993158A1 (en) * 2015-07-31 2017-02-09 Swedish Health Services Methods and compositions for characterization of glioblastoma multiforme tumors and cancer stem cells
US11499972B2 (en) 2015-09-15 2022-11-15 Swedish Health Services Methods and panels of compounds for characterization of glioblastoma multiforme tumors and cancer stem cells thereof
CN105802928A (zh) * 2016-03-30 2016-07-27 苏州偲聚生物材料有限公司 用于检测血清中mgmt抗体的多肽,检测器件和检测试剂盒
CN105796549A (zh) * 2016-04-22 2016-07-27 中国医学科学院基础医学研究所 藤黄酰胺用于制备治疗人神经胶质瘤的药物的用途
CN107475213A (zh) * 2016-06-08 2017-12-15 中国科学院苏州纳米技术与纳米仿生研究所 用于检测血清中mgmt抗体的多肽,检测器件和检测试剂盒
US11311606B2 (en) 2018-03-13 2022-04-26 Georgetown University Enhancing chemotherapy in medulloblastoma and glioblastoma with high basal p53 levels
CN110433154A (zh) * 2019-08-12 2019-11-12 昆明理工大学 藤黄酸的新用途
US20250205225A1 (en) * 2022-03-23 2025-06-26 University Of Cincinnati Methods of potentiating temozolomide activity against glioblastoma cells
CN117538458B (zh) * 2024-01-09 2024-03-29 中国医学科学院北京协和医院 同时定量分析14种单糖/二糖的液相色谱串联质谱分析方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044216A2 (en) * 1999-02-01 2000-08-03 Cytovia Inc Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis
AU2864100A (en) * 1999-02-01 2000-08-18 Cytovia, Inc. Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products
US6462041B1 (en) 1999-05-21 2002-10-08 Cytovia, Inc. Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis
JP3904364B2 (ja) 2000-03-03 2007-04-11 独立行政法人科学技術振興機構 抗マラリア活性を有する新規化合物
EP1300403A1 (en) 2001-10-02 2003-04-09 Aventis Pharma S.A. Process for the manufacture of hypoxyxylerone derivatives
WO2008148008A1 (en) * 2007-05-23 2008-12-04 Emory University High throughput bioassay for identifying selective trka receptor agonists, and gambogic amide, a selective trka agonist with neuroprotective activity
CN101289482B (zh) * 2007-09-29 2011-08-31 辽宁利锋科技开发有限公司 藤黄酸苷衍生物和类似物及其制备方法和用途
PA8851101A1 (es) * 2008-12-16 2010-07-27 Lilly Co Eli Compuesto amino pirazol

Similar Documents

Publication Publication Date Title
JP2014517025A5 (https=)
Li et al. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis
Tse et al. Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality
Chen et al. Alternative splicing of EZH2 pre-mRNA by SF3B3 contributes to the tumorigenic potential of renal cancer
Ying et al. CCT6A suppresses SMAD2 and promotes prometastatic TGF-β signaling
Meoli et al. Sex-and age-dependent effects of Gpr30 genetic deletion on the metabolic and cardiovascular profiles of diet-induced obese mice
RU2014101070A (ru) Ингибирующие глиобластому соединения и их применение
ES2788952T3 (es) Método y kits para identificación de inhibidores CDK9 para el tratamiento de cáncer
JP2017099394A (ja) ヘッジホッグ阻害剤療法のためのバイオマーカー
Wu et al. The non-coding RNA llme23 drives the malignant property of human melanoma cells
CA2783743A1 (en) Phosphatidylinositol-3-kinase pathway biomarkers
US12410152B2 (en) Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
Kechele et al. Orphan Gpr182 suppresses ERK-mediated intestinal proliferation during regeneration and adenoma formation
Shang et al. FAK kinase activity is required for the progression of c-MET/β-catenin-driven hepataocellular carcinoma
US7531318B2 (en) Screening of agents for activity against ischemic myocardial insults
Zhao et al. S100 calcium-binding protein A4 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas
Feng et al. Multilevel Regulation of NF‐κB Signaling by NSD2 Suppresses Kras‐Driven Pancreatic Tumorigenesis
JP2010514421A5 (https=)
JP5481619B2 (ja) デノボ癌を自然発症するモデル動物及びその用途
EP2027294A2 (en) Cooperating oncogenes in cancer
US20060162000A1 (en) Development and use of a new orthotopic, genetically tractable non-human animal model for liver cancer
JP2015506665A5 (https=)
DeWitt et al. The effect of 1, 25 dihydroxyvitamin D3 treatment on the mRNA levels of β catenin target genes in mice with colonic inactivation of both APC alleles
Vasilaki et al. Dll1 Marks cells of origin of Ras-induced cancer in mouse squamous epithelia
US20060110390A1 (en) Inhibition of Ku as a treatment for cardiovascular diseases